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Dermatological allergyAbstract Dexmedetomidine a highly selective a2 agonist has become a frequently used drug in
anesthesiologists’s armamentarium due to its sedative, anxiolytic, analgesic, neuroprotective and
anesthetic sparing effects and a favorable side effect proﬁle. Dexmedetomidine–lignocaine combina-
tion has been used recently to provide Bier’s block and was shown to improve quality of anesthesia,
to reduce tourniquet pain and to reduce postoperative anesthetic requirement in patients undergoing
forearm or hand surgeries. Hypotension and bradycardia are the commonly seen side effects. Only
one case of dexmedetomidine skin allergy has been reported till date in literature. We present a case
of dermatological allergy to dexmedetomidine, in a patient administered Bier’s block with dexmede-
tomidine–lignocaine combination for implant removal surgery of forearm.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.D license.1. Introduction
Bier’s block was ﬁrst described in 1908 for anesthesia of hand
and forearm and is a simple and reliable technique specially for
day care surgeries. Lidocaine is the standard local anesthetic
used in Bier’s block but many additives are now being used
to decrease the time of onset of block, prolong the duration
of block, decrease the tourniquet pain and to achieve postop-
erative analgesia [1].
Recently a2 adrenergic agonists are commonly being used
in anesthesia practice due to their sedative, analgesic, cardio-
vascular stabilizing effects and low incidence of side effects.
They also prolong the LA-induced analgesia when used in
regional blocks [2,3]. Addition of clonidine or dexmedetomi-
dine to lignocaine in Bier’s block reduces the time of onset
320 K. Marodkar et al.of block, improves the tolerance to tourniquet pain and de-
creases post-operative analgesic requirements [4].
Dexmedetomidine, a highly selective a2 agonist, is eight
times more selective for a2 adrenoceptors than clonidine. Bra-
dycardia and hypotension are the commonly seen side effects
and skin rash has been reported in one patient.
We report a case of a severe rash due to dexmedetomidine
in a 25 years old male patient posted for elective surgery of re-
moval of right radial plate under Bier’s block with combina-
tion of lignocaine–dexmedeomidine.
We obtained the patients’ permission for publishing this
case.
2. Case description
A 25 years old, 50 kg American Society of Anaesthesiologists
(ASA) Class I male patient was scheduled for elective surgery
for removal of left radial plate. The plating was done one year
ago for fracture left radius due to road trafﬁc accident. The
plating was performed under general anesthesia (propofol,
vecuronium, isoﬂurane anesthesia) an year ago. Intravenous
regional anesthesia with dexmedetomidine–lidocaine combina-
tion was planned.
A written informed consent was obtained from the patient.
The patient had no previous exposure to local anesthetic. So
sensitivity testing for lidocaine was done one day prior to sur-
gery by an intradermal injection of 0.1 ml of 2% preservative-
free plain lignocaine on the ventral aspect of forearm. There
was no erythema or wheal and the test was non-reactive. An
intravenous cannula 20G was inserted on the dorsum of
non-operative hand and ﬁrst dose of injection ceftriaxone
1 gm was administered on the morning of the day prior to sur-
gery for peri-operative antibiotic coverage. On the night prior
to surgery, tablet ranitidine hydrochloride 150 mg per oral and
intravenous ceftriaxone 1 gm (second dose) was administered.
On the day of surgery, after conﬁrming nil-by-mouth sta-
tus, standard monitors including 5-lead electrocardiography,
non-invasive blood pressure (NIBP) and pulse oximetry probe
were used (Datex Ohmeda AESTIVA 5, GE Healthcare, Hel-
sinki, Finland). A 22G intravenous (IV) cannula was inserted
on the dorsum of the hand to be operated on, for administra-
tion of Bier’s block. Infusion of Ringer Lactate was started
through the intravenous cannula present on the non-operative
hand. Premedication was achieved with intravenous ondanse-
tron 4 mg and intravenous ranitidine hydrochloride 50 mg
and the third dose of antibiotic (intravenous ceftriaxone
1 gm) was administered.
A double tourniquet (Diamond Tourniquet, Industrial
Electronic and Allied Products, Pune, India) was positioned
on the upper aspect of the operative arm. The operative
extremity was exsanguinated by elevation for 3 min and wrap-
ping it with a 10 cm Esmarch bandage. The proximal tourni-
quet was inﬂated to 250 mm of Hg (systolic BP = 124 mm
of Hg) and the Esmarch bandage was removed. Circulatory
isolation of the operative hand was conﬁrmed by absence of
the radial pulse and disappearance of the pulse oximetry
tracing.
The Bier’s block was achieved using preservative-free 0.5%
lidocaine in the dose of 3 mg kg1 [LOXICARD*, NEON
LABORATORIES LIMITED, Andheri(East), Mumbai,
India.] i.e. for 50 kg patient, 7.5 ml 2% lidocaine diluted with
saline to a total volume of 40 ml to which dexmedetomidinehydrochloride 0.5 lg kg1 [DEXTOMID*, NEON
LABORATORIES LIMITED, Andheri(East), Mumbai,
India] was added. The dexmedetomidine–lignocaine combina-
tion was administered slowly over one minute via the IV
cannula on the operative limb.
Approximately 90 s after the injection, a wheal and ﬂare
type of rash was noted in the operative limb. Such rash was
not seen on any other aspect of the patient’s body (see photo-
graph). Rash occurred 25–30 min after antibiotic injection and
90 s after administration of Bier’s block. Immediately injection
hydrocortisone 100 mg was administered via the cannula on
the operative limb. On questioning, the patient denied to the
presence of any feelings of giddiness, nausea or breathlessness.
Prophylactic injection hydrocortisone 100 mg was also admin-
istered via the cannula on non-operative limb. Oxygen supple-
mentation was done via facemask at 5 l per minute. The
patient’s vitals were closely monitored at one minute intervals.
Vitals remained stable and bronchospasm, hypotension, bra-
dycardia or arrhythmias were not observed. Approximately
10 min after this episode and 20 min after administration of
Bier’s block, when the sensory and motor blocks were con-
ﬁrmed, the distal tourniquet was inﬂated to 250 mm of Hg,
proximal tourniquet was deﬂated, intravenous cannula on
the operative limb removed and surgery commenced.
The surgery proceeded uneventfully and was completed in
75 min. At that time, reduction in the allergic rash was noted
but it was still present. There was no tourniquet pain and so
the patient was kept under observation in the operating room.
Keeping resuscitation equipment and drugs ready, the distal
tourniquet was released at 120 min after administration of
Bier’s block. At the time of release of tourniquet only minimal
rash was present. The patient’s hemodynamic vitals remained
stable.
Monitoring was continued in the operating room but signs
of rash anywhere else on the body or signs of hemodynamic
instability were not observed. The patient was shifted to the
post-anesthesia care unit after one hour. The rash completely
resolved 4 h after its appearance and patient was shifted
toward after 24 h.3. Discussion
Our patient, a 25 years old male, who had undergone ﬁxation
of left radius fracture an year ago under an uneventful general
anesthesia using Propofol, vecuronium and isoﬂurane was
scheduled for radial plate removal surgery. Decision to con-
duct surgery under intravenous regional anesthesia was taken.
There was no history of exposure to local anesthesia in past.
There was no history of any drug allergy in past.
We used 0.5% lidocaine in our patient. Sensitivity test for
lidocaine done one day prior to surgery was non-reactive.
Dexmedetomidine was approved by the Food and Drug
Administration in December 1999 for use in humans as a
short-term medication (<24 h) for analgesia and sedation in
the intensive care unit (ICU). The adverse effects of dexmede-
tomidine include hypotension, hypertension, nausea, bradycar-
dia and atrial ﬁbrillation. Most of the adverse events
associated with dexmedetomidine use occur during or brieﬂy
after loading dose of the drug [5].
Jaakola et al. demonstrated the analgesic efﬁcacy of
dexmedetomidine in human tourniquet pain. In their study,
Figure 1 Wheal and ﬂare rash on operative upper extremity of
patient immediately after injection of dexmedetomidine–lidocaine
mixture in Bier’s block.
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and 1 lg/kg) was administered in healthy volunteers. They
found that dexmedetomidine clearly demonstrated an analge-
sic effect in the tourniquet test [6].
Dilek Memis et al. were the ﬁrst to demonstrate clinically
that the addition of 0.5 lg/kg dexmedetomidine to lidocaine
for IVRA improves quality of anesthesia and improves intra-
operative-postoperative analgesia without causing side effects
[4].
M.A. Abosedira in a study concluded that dexmedetomi-
dine–lidocaine mixture provided better quality of anesthesia,
tourniquet tolerance and operative and postoperative analge-
sia. The author also reported an increase in post-cuff deﬂation
sedation in dexmedetomidine–lidocaine patients as compared
to clonidine–lidocaine mixture [1].
We decided to add dexmedetomidine 0.5 lg per kg to 0.5%
lidocaine in Bier’s block to improve quality of intra-operative
anesthesia and to reduce postoperative analgesic requirement.
The proximal tourniquet was inﬂated to 250 mmHg and
dexmedetomidine–lidocaine mixture was slowly injected
through the intravenous cannula on the operative limb. A
wheal and ﬂare type of rash was encountered along the course
of the vein on the operative limb approximately 90 s after the
injection of Bier’s block.
We immediately administered intravenous hydrocortisone
through the same cannula. We also administered prophylactic
hydrocortisone through the cannula on contralateral hand.
The mechanism of action of hydrocortisone is suppression of
the inﬂammatory response by limiting the recruitment of
inﬂammatory cells at the local sites [7]. We were unsure about
the exact effect produced by such an injection of hydrocorti-
sone in Bier’s block. It was nevertheless administered as it
was the only possible step to reduce the inﬂammatory response
at the site. Systemic hydrocortisone was administered to coun-
teract the inﬂammatory mediators, if any, released after deﬂa-
tion of tourniquet.
Ludwig et al. [8] observed a similar wheal and ﬂare rash
encompassing 60% of body surface area in an intubated
patient, injured in a motor vehicle collision, 4 h after starting
dexmedetomidine infusion (0.2 lg/kg/h). The rash completely
resolved 48 h after discontinuation of dexmedetomidine
infusion.
Okabe et al. [9] reported a case of drug fever caused by
dexmedetomidine hydrochloride infusion. The patient was
transferred to the intensive care unit with an abdominal aortic
aneurysm rupture. After initiation of sedation with dexmede-
tomidine hydrochloride, he developed pyrexia of more than
39 C. This symptom improved rapidly 7 h after stopping
dexmedetomidine hydrochloride. Other possible causes (such
as infection) were sequentially eliminated.
When Naranjo adverse drug reaction probability score was
calculated, our score of 5 points indicates that there is a
‘probability’ of dexmedetomidine causing this reaction [10].
We have already ruled out the other possible agents causing
such rash namely, lidocaine, antibiotic or premedication.
This is the second case report of dermatological allergic
response to dexmedetomidine.We conclude that anesthesiologists should be aware of
allergic dermatologic reactions to dexmedetomidine specially
in the present setup, when it is being widely used as an intra-
venous analgesic and as an additive in regional anesthesia
(see Fig. 1).
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